Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
about
Tocilizumab for rheumatoid arthritisAdverse effects of biologics: a network meta-analysis and Cochrane overviewTocilizumabBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementPotential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical reviewAdvances in the treatment of rheumatoid arthritis.Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritisRefining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisIL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophiliaRemission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsClinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice.Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.Rationale of using different biological therapies in rheumatoid arthritis.Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of tSystematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.Biologic therapy for autoimmune diseases: an update.Emerging strategies and therapies for treatment of Paget's disease of bone.Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryLow baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patientsDevelopment of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6).Anti-Arthritic Effect of Chebulanin on Collagen-Induced Arthritis in Mice.A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease.Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysisAcute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient.Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
P2860
Q24234126-AC78E16F-61D5-4DBB-B133-D40F3B7E5D98Q24234197-6BBC1D9D-AA61-47AB-B4A8-796FAC4B9E96Q24655317-7E8D899E-E4D2-4E56-854F-F138B21E5F61Q26852235-254DE219-987F-4666-8DE5-1F59F49893FCQ26991673-7155C6B7-F1BA-45C0-B506-4A9A719762ACQ27021115-854CC84E-B0D6-47DC-95E8-62E8560C6683Q27024465-B3E3253D-B780-43D7-A5FD-C1635CED9893Q27691822-8B640A10-6B68-4CA1-815D-565C774A1887Q28071389-3FBE9E92-059C-4609-8475-9FBED5FB565FQ28080677-0C72E828-53B3-4A31-9F3C-BD3AA822CB70Q28547851-9A03FBC1-22FD-4AA5-B331-ADB6EE042F54Q30439206-69F8F062-204A-4DA3-8A8D-E9727699EF7DQ30612998-4EC5D7EC-F8E9-4995-BAB3-58DADF576335Q30769719-E8BDA261-A47E-4208-BBCE-696A9C1AAE61Q30882161-674F51FC-81EE-4DD8-BE21-4A7547896FCDQ33400381-C1AA5A7A-6B4B-47BB-86BE-F4AB0903132BQ33778719-73FC9008-2A71-4EDB-94B2-1E62BA1F7763Q33809045-927E744C-435C-4F01-AA07-07BB73E8E8BBQ33880319-116B93EE-9525-4301-94C4-31AAE02FCAF0Q33959754-A56C3FC8-3661-4F3C-B706-3962F48AA18AQ34153073-1CB5DA2F-A643-49BE-B428-4721BB893927Q34343286-574EA465-57DB-4CCD-B41B-419F245CDD55Q34394122-B84FD314-0A3F-4AB4-9208-2A485AB3D76EQ34523450-7B7353D6-0C51-48C0-9798-9E6C6E8B12C0Q34607794-9183B802-AB29-4C93-9818-03E943B33C4AQ34655597-A0D482B6-C3C3-4E72-BE07-918DCDEEDEF0Q34987305-547EFAE7-E880-4398-A407-48B3929832FBQ35094621-F9E3B3BE-AB56-41A2-8F3C-9EE2EB3054BFQ35237588-F44CAA4D-5691-41E6-9723-B26CFC42C741Q35258244-9BC3F59B-8EAB-41E2-9A53-82160EA0313EQ35438412-4B63458A-F236-4821-9B97-3E421BB6DFB4Q35540000-2ED8B87D-9BA2-42D9-9DBC-CE55C27E3167Q35605474-A2EE763A-D30D-4E03-99E8-48EE0DC9D7C0Q35742243-77ADD521-83C3-4BA3-8D94-F122CBBB5235Q35786676-8BF915BF-1EF9-484E-AEE6-C39C16D00DDEQ36094049-7F6DB51A-7B11-4AD7-87A9-84806442DB0AQ36245700-E939E919-9FC4-4B5F-8768-1B2E3CEDB1BDQ36443895-82338E1B-1BB1-4C80-BCCD-8B5557330D31Q36490257-62C43D2D-7D8F-487D-AB21-342F5E1D3C48Q36513512-7EA7971E-668F-4D3C-8441-EA6D3C8BC9D2
P2860
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Long-term safety and efficacy ...... y in a 5-year extension study.
@en
Long-term safety and efficacy ...... y in a 5-year extension study.
@nl
type
label
Long-term safety and efficacy ...... y in a 5-year extension study.
@en
Long-term safety and efficacy ...... y in a 5-year extension study.
@nl
prefLabel
Long-term safety and efficacy ...... y in a 5-year extension study.
@en
Long-term safety and efficacy ...... y in a 5-year extension study.
@nl
P2093
P2860
P356
P1476
Long-term safety and efficacy ...... cy in a 5-year extension study
@en
P2093
P2860
P304
P356
10.1136/ARD.2008.092866
P407
P577
2008-11-19T00:00:00Z